Placebo for liraglutide

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC, Per-Ola Carlsson

Conditions

Type 1 DiabetesType 2 Diabetes Mellitus

Phase 1

Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)

CompletedNCT01373450

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2011-06-30End: 2011-07-31Updated: 2015-09-02

Phase 2

Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes

CompletedNCT02617654

Per-Ola CarlssonType 1 Diabetes

Start: 2015-11-30End: 2020-09-30Updated: 2020-11-05

Related Papers

Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series

American Journal of Physiology-Endocrinology and Metabolism2016-04-137 citations